Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Vale CL, Godolphin PJ, Fisher DJ, Higgins JPT, McAleenan A, Spiga F, Tritschler T, de Barros E Silva PGM, Berg DD, Berger JS, Berry LR, Bikdeli B, Blondon M, Bohula EA, Cattaneo M, Colombo R, Coluccio V, DeSancho MT, Farkouh ME, Fuster V, Girardis M, Hochman JS, Jensen TP, Jha V, Jüni P, Kirtane AJ, Lawler P, Le Gal G, Lecumberri R, Lentz SR, Lopes RD, Lorenzi E, Marietta M, Miranda CH, Morici N, Morpeth SC, Morrow DA, McQuilten ZK, Muñoz-Rivas N, Neal MD, Pant S, Parikh SA, Perepu U, Sadeghipour P, Sethi S, Sholzberg M, Spyropoulos AC, Stone GW, Talasaz AH, Tong S, Totterdell J, Venkatesh B, Wu MA, Zarychanski R, Zuily S, Viry J, Rylance J, Adhikari NKJ, Diaz JV, Marshall JC, Sterne JAC, Murthy S. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. Among authors: lentz sr. Ann Intern Med. 2024 Dec 24. doi: 10.7326/ANNALS-24-00800. Online ahead of print. Ann Intern Med. 2024. PMID: 39715559 Free article. Review.
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; ADVANCE Investigator Study Group. Broome CM, et al. Lancet. 2023 Nov 4;402(10413):1648-1659. doi: 10.1016/S0140-6736(23)01460-5. Epub 2023 Sep 28. Lancet. 2023. PMID: 37778358 Clinical Trial.
A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase.
Ragavan VN, Nair PC, Jarzebska N, Angom RS, Ruta L, Bianconi E, Grottelli S, Tararova ND, Ryazanskiy D, Lentz SR, Tommasi S, Martens-Lobenhoffer J, Suzuki-Yamamoto T, Kimoto M, Rubets E, Chau S, Chen Y, Hu X, Bernhardt N, Spieth PM, Weiss N, Bornstein SR, Mukhopadhyay D, Bode-Böger SM, Maas R, Wang Y, Macchiarulo A, Mangoni AA, Cellini B, Rodionov RN. Ragavan VN, et al. Among authors: lentz sr. Nat Commun. 2023 Jun 9;14(1):3392. doi: 10.1038/s41467-023-38467-9. Nat Commun. 2023. PMID: 37296100 Free PMC article.
Characterization of bleeding symptoms in Ehlers-Danlos syndrome.
Kumskova M, Flora GD, Staber J, Lentz SR, Chauhan AK. Kumskova M, et al. Among authors: lentz sr. J Thromb Haemost. 2023 Jul;21(7):1824-1830. doi: 10.1016/j.jtha.2023.04.004. Epub 2023 Apr 17. J Thromb Haemost. 2023. PMID: 37179130 Free article.
201 results